Skip to main content
SpringerLink
Log in

Stellenwert neuer Behandlungsansätze mit Targettherapeutika bei malignen Schilddrüsenerkrankungen

Highlights vom ASCO-Kongress 2011

Current status of therapeutic approaches with targeted therapies in malignant thyroid cancer

Highlights from the 2011 ASCO Congress

  • Leitthema
  • Published:
HNO Aims and scope Submit manuscript

Zusammenfassung

Das große Interesse an der Behandlung lokal fortgeschrittener oder bereits metastasierter Schilddrüsenkarzinome spiegelt sich durch die hohe Anzahl an eingereichten und bewilligten Kongressbeiträgen auf dem Jahreskongress der „American Society of Clinical Oncology“ (ASCO-Kongress) 2011 wider. Viele Patienten mit differenzierten, undifferenzierten und medullären Schilddrüsenkarzinomen sprechen auf bisher etablierte Therapieverfahren nicht mehr ausreichend an, sodass Hoffnung in neuere Therapiestrategien gesetzt wird. Bei diesen Therapieverfahren handelt es sich vor allem um Targettherapeutika, die biologisch gezielt zentrale Signalkaskaden in den veränderten Zellen bekämpfen, insbesondere die Angiogenese dieser Tumoren. Der Kliniker sollte die Möglichkeiten dieser Therapie kennen und mit den typischen Nebenwirkungen vertraut seien.

Abstract

Increasing interest in the treatment of locally advanced and already metastasized thyroid cancer is reflected in the high number of submitted and accepted conference papers at the annual meeting of the American Society of Clinical Oncology (ASCO Congress) 2011. Many patients suffering from differentiated, undifferentiated and medullary thyroid cancer do not respond to established therapeutic procedures, so that new strategies have to be developed. Targeted biological agents are a new and promising therapeutic method that selectively affects complex signaling cascades, especially angiogenesis, of the malignant cells. Clinicians and researchers should understand the potential of these therapeutic strategies and be aware of the typical side effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Akeno-Stuart N, Croyle M, Knauf JA et al (2007) The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells. Cancer Res 67:6956–6964

    Article  PubMed  CAS  Google Scholar 

  2. Bible KC, Suman VJ, Molina JR et al (2009) Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol 10:962–972

    Google Scholar 

  3. Carr L, Goulart B, Martins R et al (2009) Phase II trial of continuous dosing of sunitinib in advanced, FDG-PET avid, medullary thyroid carcinoma (MTC) and well-differentiated thyroid cancer (WDTC). J Clin Oncol 27:6056

    Google Scholar 

  4. Cohen, EE, Needles BM, Cullen KJ et al (2008) Phase 2 study of sunitinib in refractory thyroid cancer. J Clin Oncol 26:6025

    Google Scholar 

  5. Cohen EE, Rosen LS, Vokes EE et al (2008) Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 26:4708–4713

    Article  PubMed  CAS  Google Scholar 

  6. Cooper DS, Doherty GM, Haugen BR et al (2009) Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19(11):1167–1214

    Article  PubMed  Google Scholar 

  7. Flaherty KT, Puzanov I, Kim KB et al (2009) Phase I study of PLX4032: proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J Clin Oncol 27:9000

    Google Scholar 

  8. Fury MG, Solit DB, Su YB et al (2007) A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol 59:467–475

    Article  PubMed  CAS  Google Scholar 

  9. Gramza AW, Wells SA, Balasubramaniam S, Fojo AT (2011) Phase I/II trial of vandetanib and bortezomib in adults with locally advanced or metastatic medullary thyroid cancer: Phase I results. J Clin Oncol 29:5565

    Google Scholar 

  10. Grande Pulido E, Castelo P, Fonseca PJ et al (2011) Efficacy and tolerability of sunitinib in patients with advanced thyroid cancer out of a trial: A Spanish multicenter cohort. J Clin Oncol 29:16024

    Google Scholar 

  11. Gupta-Abramson V, Troxel AB, Nellore A et al (2008) Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 26:4714–4719

    Article  PubMed  CAS  Google Scholar 

  12. Ha HT, Lee JS, Urba S et al (2010) A phase II study of imatinib in patients with advanced anaplastic thyroid cancer. Thyroid 20:975–980

    Article  PubMed  CAS  Google Scholar 

  13. Haugen BR (1999) Management of the patient with progressive radioiodine nonresponsive disease. Semin Surg Oncol 16:34–41

    Article  PubMed  CAS  Google Scholar 

  14. Inai T, Mancuso M, Hashizume H et al (2004) Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 165:35–52

    Article  PubMed  CAS  Google Scholar 

  15. Keefe SM, Troxel AB, Rhee S et al (2011) Phase II trial of sorafenib in patients with advanced thyroid cancer. J Clin Oncol 29:5562

    Google Scholar 

  16. Kurzrock R, Sherman SI, Ball DW et al (2011) Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 29:2660–2666

    Article  PubMed  CAS  Google Scholar 

  17. Liu D, Hou P, Liu Z et al (2009) Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin. Cancer Res 69:7311–7319

    Article  PubMed  CAS  Google Scholar 

  18. Liu D, Xing M (2008) Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-kappaB pathways. Thyroid 18:853–864

    Article  PubMed  Google Scholar 

  19. Nagaiah G, Fu P, Wasman JK et al (2009) Phase II trial of sorafenib (BAY 43–9006) in patients with advanced anaplastic carcinoma of the thyroid (ATC). J Clin Oncol 27:6058

    Google Scholar 

  20. Ravaud A, Fouchardière C, Courbon F et al (2008) Sunitinib in patients with refractory advanced thyroid cancer: the THYSU phase II trial. J Clin Oncol 26:6058

    Article  Google Scholar 

  21. Salvatore G, De Falco V, Salerno P et al (2006) BRAF is a therapeutic target in aggressive thyroid carcinoma. Clin Cancer Res 12:1623–1629

    Article  PubMed  CAS  Google Scholar 

  22. Salgia R, Sherman S, Hong DS et al (2008) A phase I study of XL184, a RET, VEGFR2, and MET kinase inhibitor, in patients (pts) with advanced malignancies, including pts with medullary thyroid cancer (MTC). J Clin Oncol 26:3522

    Google Scholar 

  23. Schlumberger MJ (1998) Papillary and follicular thyroid carcinoma. N Engl J Med 338:297–306

    Article  PubMed  CAS  Google Scholar 

  24. Schlumberger M, Elisei R, Bastholt L et al (2009) Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 27:3794–3801

    Article  PubMed  CAS  Google Scholar 

  25. Schwartz GK, Robertson S, Shen A et al (2009) A phase I study of XL281, a selective oral RAF kinase inhibitor, in patients (Pts) with advanced solid tumors. J Clin Oncol 27:3513

    Article  Google Scholar 

  26. Sherman SI, Wirth LJ, Droz JP et al (2008) Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 359:31–42

    Article  PubMed  CAS  Google Scholar 

  27. Strumberg D, Clark JW, Awada A et al (2007) Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 12:426–437

    Article  PubMed  CAS  Google Scholar 

  28. Wells SA Jr, Gosnell JE, Gagel RF et al (2010) Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 28:767–772

    Article  PubMed  CAS  Google Scholar 

  29. Wells SA, Robinson G, Gagel RF et al (2010) Vandetanib (VAN) in locally advanced or metastatic medullary thyroid cancer (MTC): A randomized, double-blind phase III trial (ZETA). J Clin Oncol 28:5503

    Article  Google Scholar 

  30. Woyach JA, Shah MH (2009) New therapeutic advances in the management of progressive thyroid cancer. Endocr Relat Cancer 16:715–731

    Article  PubMed  CAS  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor weist auf folgende Beziehungen hin: Dr. F.C. Uecker gibt an, dass kein Interessenkonflikt besteht. Prof. Dr. R. Knecht ist als wissenschaftlicher Berater für Merck Serono und Sanofi Aventis tätig.

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Hals-, Nasen- und Ohrenheilkunde, Charité - Universitätsmedizin Berlin, Campus Charité Mitte, Charitéplatz 1, 10117, Berlin, Deutschland

    F.C. Uecker

  2. Klinik und Poliklinik für Hals-, Nasen- und Ohrenheilkunde, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland

    S. Laban & R. Knecht

Authors
  1. F.C. Uecker
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Laban
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Knecht
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F.C. Uecker.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Uecker, F., Laban, S. & Knecht, R. Stellenwert neuer Behandlungsansätze mit Targettherapeutika bei malignen Schilddrüsenerkrankungen. HNO 60, 398–403 (2012). https://doi.org/10.1007/s00106-011-2464-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00106-011-2464-z

Schlüsselwörter

Keywords

Search

Navigation